Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

NBQX

AMPA/kainate receptor antagonist
 
ALX-550-044-M005 5 mg 75.00 USD
 
ALX-550-044-M025 25 mg 279.00 USD
Do you need bulk/larger quantities?
 
Most potent and selective AMPA/kainate receptor antagonist. For the more soluble form see NBQX . disodium salt (Prod. No. ALX-550-272).

Product Specification

Alternative Name:2,3-Dihydroxy-6-nitro-7-sulphamoylbenzo(f)-quinoxaline, 6-Nitro-7-sulphamoylbenzo(f)-quinoxaline-2,3-dione
 
Formula:C12H8N4O6S
 
MW:336.3
 
CAS:118876-58-7
 
Purity:≥99% (HPLC)
 
Appearance:Yellow crystalline powder.
 
Solubility:Soluble in DMSO. A 1mM aqueous solution may be prepared by taking up in >2.5 eq. of NaOH and backtitrating to pH 8.0-8.5 with conc. HCl.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Handling:Protect from light.
 
ALX-550-044
Please mouse over
ALX-550-044

Product Literature References

Emerging treatments for stroke in humans: W.J. Koroshetz & M.A. Moskowitz; TIPS 17, 227 (1996), (Review), Abstract;
Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f] quinoxaline: H. Bernert & L. Turski; PNAS 93, 5235 (1996), Abstract;
Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy: T. Namba, et al.; Brain Res. 638, 36 (1994), Abstract;
A comparison of the actions of agonists and antagonists at non-NMDA receptors of C fibres and motoneurones of the immature rat spinal cord in vitro: P. Pook, et al.; Br. J. Pharmacol. 108, 179 (1993), Abstract;
AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?: A.M. Buchan, et al.; Stroke 24, I148 (1993), Abstract;
The pharmacology of AMPA receptors and their antagonists: M.J. Sheardown; Stroke 24, I146 (1993), Abstract;
Competitive inhibition by NBQX of kainate/AMPA receptor currents and excitatory synaptic potentials: importance of 6-nitro substitution: J.C. Randle, et al.; Eur. J. Pharmacol. 215, 237 (1992), Abstract;
The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl- benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model: R. Gill, et al.; Brain Res. 580, 35 (1992), Abstract;
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia: M.J. Sheardown, et al.; Science 247, 571 (1990), Abstract;
Contributions of quisqualate and NMDA receptors to the induction and expression of LTP: D. Muller, et al.; Science 242, 1694 (1988), Abstract;

Related Products

NBQX . disodium salt 

AMPA/kainate receptor antagonist
118876-58-7 (non-salt), ≥98% (HPLC) | Print as PDF
 
ALX-550-272-M005 5 mg 112.00 USD
 
ALX-550-272-M025 25 mg 443.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,